Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Open access
Sun, Qiaoling, Zhou, Jinghong, Zhang, Zheng, Guo, Mingchuan, Liang, Junqing, Zhou, Feng, Long, Jingwen, Zhang, Wei, Yin, Fang, Cai, Huaqing, Yang, Haibin, Zhang, Weihan, Gu, Yi, Ni, Liang, Sai, Yang, Cui, Yumin, Zhang, Meifang, Hong, Minhua, Sun, Junen, Yang, Zheng, Qing, Weiguo, Su, Weiguo, Ren, Yongxin · 2014 · Cancer Biology & Therapy

Abstract

VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies. One challenging aspect in small molecular VEGFR inhibitors is to achieve sustained target inhibition at tolerable doses previously seen only with the long-acting biologics. It would require high potency (low effective drug concentrations) and sufficient drug exposures at tolerated doses so that the drug concentration can be maintained above effective drug concentration for target inhibition within the dosing period. Fruquintinib (HMPL-013) is a small molecule inhibitor with strong potency and high selectivity against VEGFR family currently in Phase II clinical studies. Analysis of Phase I pharmacokinetic data revealed that at the maximum tolerated dose of once daily oral administration fruquintinib achieved complete VEGFR2 suppression (drug concentrations were maintained above that required to produce >85% inhibition of VEGFR2 phosphorylation in mouse) for 24 hours/day. In this article, the preclinical data for fruquintinib will be described, including kinase enzyme activity and selectivity, cellular VEGFR inhibition and VEGFR-driven functional activity, in vivo VEGFR phosphorylation inhibition in the lung tissue in mouse and tumor growth inhibition in a panel of tumor xenograft and patient derive xenograft models in mouse. Pharmacokinetic and target inhibition data are also presented to provide a correlation between target inhibition and tumor growth inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/15384047.2014.964087

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 159

Metadata

Authors
Sun, Q., Zhou, J., Zhang, Z., Guo, M., Liang, J., Zhou, F., Long, J., Zhang, W., Yin, F., Cai, H., Yang, H., Zhang, W., Gu, Y., Ni, L., Sai, Y., Cui, Y., Zhang, M., Hong, M., Sun, J., Yang, Z., Qing, W., Su, W., & Ren, Y.
Venue
Cancer Biology & Therapy
Published
2014-10-29
Volume
15
Issue
12
Pages
1635-1645
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
OpenAlex
W2007058673
Cited by
159
References
2
FWCI
0.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.